SCHEDULE: Nantahala Capital Reveals 8.22% Immunic Stake

Nantahala Capital Management, LLC and its managing members have disclosed an 8.22% beneficial ownership stake in Immunic, Inc., including shares from warrants.

Summary

• Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, collectively reported beneficial ownership of 10,378,406 shares of Immunic, Inc. Common Stock.
• This ownership represents 8.22% of Immunic, Inc.'s outstanding common stock as of December 31, 2025.
• The reported shares include 6,000,000 shares that may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• The Reporting Persons hold shared voting and shared dispositive power over all 10,378,406 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The disclosure of a significant institutional stake by Nantahala Capital suggests a vote of confidence in Immunic, Inc., which is generally favorable for investor sentiment.

Positives

• A significant institutional investor, Nantahala Capital Management, LLC, has disclosed a substantial 8.22% stake in Immunic, Inc., which can be interpreted as a vote of confidence in the company's prospects.
• The inclusion of 6,000,000 shares from exercisable warrants within the beneficial ownership indicates a potential long-term commitment or strategic interest from the investor.

Risks

• Concentration of ownership by a single institutional investor and its principals could lead to significant share price volatility if their investment strategy changes or they decide to reduce their stake.

Future Outlook

NA

Management Comments

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack certified that the securities were acquired and are held in the ordinary course of business.
• The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Immunic, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that significant institutional ownership, especially from an investment adviser like Nantahala Capital, often signals confidence in a company's long-term prospects. In the biotechnology sector, where Immunic, Inc. operates, such endorsements can be particularly impactful, suggesting a belief in the company's pipeline or strategic direction.

Stakeholder Impact

• Shareholders may perceive this as a positive signal, potentially increasing confidence in Immunic, Inc.'s stock due to the backing of a notable institutional investor.
• The presence of a significant shareholder could influence future strategic decisions or corporate governance, although the filing states the stake is not for control purposes.

Key Dates

Recommendation

The disclosure of a substantial stake by a reputable investment firm like Nantahala Capital suggests a vote of confidence in Immunic, Inc.'s long-term value proposition. While not a direct catalyst for immediate action, it warrants continued monitoring and could indicate underlying strength, justifying a 'hold' recommendation for existing investors and further due diligence for potential new investors.

Keywords

Immunic Inc, Nantahala Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Warrants, Biotechnology